Celltrion Pharm, Inc. (068760.KQ)
KRW 48000.0
(1.27%)
KRW 48000.0
(1.27%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 36.07 Billion KRW | -5.63% |
| 2022 | 38.17 Billion KRW | -20.12% |
| 2021 | 47.78 Billion KRW | 102.21% |
| 2020 | 23.63 Billion KRW | 60.34% |
| 2019 | 14.73 Billion KRW | 365.54% |
| 2018 | 3.16 Billion KRW | -63.24% |
| 2017 | 8.61 Billion KRW | 157.1% |
| 2016 | -15.08 Billion KRW | -337.3% |
| 2015 | 6.35 Billion KRW | 76446.98% |
| 2014 | 8.3 Million KRW | 8.59% |
| 2013 | 7.64 Million KRW | 132.02% |
| 2012 | 3.29 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 3.68 Billion KRW | -28.24% |
| 2024 Q2 | 9.41 Billion KRW | 155.28% |
| 2023 Q3 | 6.55 Billion KRW | -55.65% |
| 2023 Q4 | 5.14 Billion KRW | -21.52% |
| 2023 FY | 36.02 Billion KRW | -5.63% |
| 2023 Q1 | 9.55 Billion KRW | 56.97% |
| 2023 Q2 | 14.77 Billion KRW | 54.62% |
| 2022 FY | 38.17 Billion KRW | -20.12% |
| 2022 Q4 | 6.08 Billion KRW | -54.79% |
| 2022 Q1 | 7.76 Billion KRW | -8.81% |
| 2022 Q3 | 13.46 Billion KRW | 24.0% |
| 2022 Q2 | 10.85 Billion KRW | 39.91% |
| 2021 Q3 | 13 Billion KRW | -21.79% |
| 2021 Q4 | 8.51 Billion KRW | -34.56% |
| 2021 Q2 | 16.62 Billion KRW | 72.5% |
| 2021 Q1 | 9.63 Billion KRW | 125941.06% |
| 2021 FY | 47.78 Billion KRW | 102.21% |
| 2020 Q3 | 5.84 Million KRW | 1.78% |
| 2020 FY | 23.63 Billion KRW | 60.34% |
| 2020 Q4 | 7.64 Million KRW | 30.74% |
| 2020 Q2 | 5.74 Million KRW | 31.05% |
| 2020 Q1 | 4.38 Million KRW | -16.82% |
| 2019 FY | 14.73 Billion KRW | 365.54% |
| 2019 Q3 | 3.99 Million KRW | 9.67% |
| 2019 Q1 | 1.83 Million KRW | -56.85% |
| 2019 Q4 | 5.27 Million KRW | 32.01% |
| 2019 Q2 | 3.64 Million KRW | 98.98% |
| 2018 Q2 | -269.53 Thousand KRW | -119.15% |
| 2018 FY | 3.16 Billion KRW | -63.24% |
| 2018 Q1 | 1.4 Million KRW | 6.66% |
| 2018 Q4 | 4.24 Million KRW | 291.61% |
| 2018 Q3 | -2.21 Million KRW | -721.24% |
| 2017 Q1 | -955.36 Thousand KRW | 95.5% |
| 2017 Q2 | 4.85 Million KRW | 607.98% |
| 2017 FY | 8.61 Billion KRW | 157.1% |
| 2017 Q4 | 1.31 Million KRW | -61.13% |
| 2017 Q3 | 3.39 Million KRW | -30.04% |
| 2016 Q3 | 2.05 Million KRW | 6.14% |
| 2016 FY | -15.08 Billion KRW | -337.3% |
| 2016 Q1 | 2.13 Million KRW | 111.5% |
| 2016 Q2 | 1.94 Million KRW | -9.25% |
| 2016 Q4 | -21.22 Million KRW | -1130.56% |
| 2015 Q3 | 1.5 Million KRW | -15.38% |
| 2015 Q2 | 1.77 Million KRW | 0.19% |
| 2015 Q1 | 1.77 Million KRW | -37.96% |
| 2015 FY | 6.35 Billion KRW | 76446.98% |
| 2015 Q4 | -18.59 Million KRW | -1336.28% |
| 2014 Q3 | 2.38 Million KRW | 3.69% |
| 2014 FY | 8.3 Million KRW | 8.59% |
| 2014 Q4 | 2.85 Million KRW | 19.73% |
| 2014 Q2 | 2.3 Million KRW | 206.19% |
| 2014 Q1 | 752.34 Thousand KRW | -51.32% |
| 2013 Q3 | 1.97 Million KRW | -8.45% |
| 2013 FY | 7.64 Million KRW | 132.02% |
| 2013 Q1 | 1.97 Million KRW | 87.19% |
| 2013 Q4 | 1.54 Million KRW | -21.64% |
| 2013 Q2 | 2.15 Million KRW | 9.07% |
| 2012 Q4 | 1.05 Million KRW | 0.0% |
| 2012 FY | 3.29 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 284.579% |
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | -530.034% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 70.656% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | 46.061% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | 351.256% |
| Humedix Co., Ltd. | 37.31 Billion KRW | 3.322% |
| Boditech Med Inc. | 33.44 Billion KRW | -7.857% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | -368.505% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | 529.01% |
| Huons Co., Ltd. | 59.79 Billion KRW | 39.675% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | -233.411% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | 320.299% |